Comparing Fusion Detection Assays Using Sarcoma Samples

August 24, 2017

In this webinar, Professor Florian Haller from the University Hospital Erlangen shares data from reliable and sensitive RNA fusion detection assays. His data compare TruSight[Symbol] RNA Pan Cancer Panel (1385 target genes), TruSight RNA Fusion Panel (507 target genes), and Archer FusionPlex[Symbol] (85 target genes) assays from sarcoma samples. To learn more about Cancer Clinical Research, visit https://www.illumina.com/areas-of-interest/cancer/clinical-cancer-research.html View related video: Identification of Novel Fusion and Pharmacogenomic Targets in Cancer https://www.youtube.com/watch?v=TZLAul5qdqk&t=507s Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc For Research Use Only. Not for use in diagnostic procedures.

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.